References
Conner E, Miles AM, Aiko S, et al. Reactive oxygen metabolites: therapeutic implications of their role in inflammatory disease. Clin Immunother 1995 Jun; 3(6): 438–49
Jadot G, Vaille A, Maldonado J, et al. Clinical pharmacokinetics and delivery of bovine Superoxide dismutase. Clin Pharmacokinet 1995 Jan; 28(1): 17–25
Maxwell SRJ. Prospects for the use of antioxidant therapies. Drugs 1995 Mar; 49(3): 345–61
Schneeberger H, Schleibner S, Schilling M, et al. Prevention of acute renal failure after kidney transplantation by treatment with rh-SOD: interim analysis of a double-blind placebo-controlled trial. Transplant Proc 1990 Oct; 22(5): 2224–5
Pollak R, Andrisevic JH, Maddux MS, et al. A randomized double-blind trial of the use of human recombinant Superoxide dismutase in renal transplantation. Transplantation 1993 Jan; 55(1): 57–60
Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant Superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994 Jan; 57(2): 211–7
Stein J. PEG-SOD offers new hope for patients with severe head injury. Inpharma 1993 Aug 7; (899): 15
Henahan S. Latest products of neural research. Inpharma 1994 Dec 17; (968): 17
Rights and permissions
About this article
Cite this article
Superoxide dismutase has wide clinical potential. Drugs Ther. Perspect 6, 8–9 (1995). https://doi.org/10.2165/00042310-199506050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199506050-00003